Investors & Media

Immorna has successfully closed 3 rounds of financing with a total of 8 investors, including leading venture capitals and industry investors.

We welcome new investors. For investment
opportunities, please contact ir@immornabio.com
News Flow

News Update
Immorna Biotherapeutics Presents Clinical Data for JCXH-211, a Self-Replicating RNA Encoding the Human IL-12, at ASCO 2024

Immorna Biotherapeutics PresentsClinical Data for JCXH-211, a Self-Replicating RNA Encoding the Huma...
2024.06

News Update
Immorna Announces First Subject Dosed in a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Vaccine Developed for the Prevention of Shingles

MORRISVILLE, N.C., May 30, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company f...
2023.05

News Update
Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine

MORRISVILLE, N.C., January 9, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology compan...
2023.01

News Update
Immorna Receives IND Clearance to Conduct a Phase 1/2 Study of JCXH-221, a Broadly Protective mRNA-Based COVID-19 Vaccine

MORRISVILLE, N.C., November 21st, 2022 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology co...
2022.11